Several studies have shown that PAI-1 is increased in adipose tissue and plasma in obese humans and that plasma PAI-1 concentrations decrease after weight loss or fasting [42,43], which suggests a role for this proteinase inhibitor in the development and maintenance of obesity. Here, SERPINE1 is linked to obesity disorder.